Maarten van der Doelen

General discussion and future perspectives

38. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naivemenwithmetastatic castration resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013;14(12):1193-9. 39. Bahl A, Oudard S, Tombal B, Ozgüroglu M, Hansen S, Kocak I, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration resistant prostate cancer treated in the TROPIC trial. Ann Oncol. 2013;24(9):2402-8. 40. Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15(10):1147-56. 41. LoriotY, Miller K, SternbergCN, Fizazi K, De Bono JS, Chowdhury S, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16(5):509-21. 42. Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O’Sullivan JM, et al. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol. 2016;27(5):868-74. 43. Bottomley A, Pe M, Sloan J, Basch E, Bonnetain F, Calvert M, et al. Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol. 2016;17(11):e510-e4. 44. Kretschmer A, Ploussard G, Heidegger I, Tsaur I, Borgmann H, Surcel C, et al. Health-related Quality of Life in Patients with Advanced Prostate Cancer: A Systematic Review. Eur Urol Focus. 2021;7(4):742-51. 45. Parikh S, Murray L, Kenning L, Bottomley D, Din O, Dixit S, et al. Real-world Outcomes and Factors Predicting Survival and Completion of Radium 223 in Metastatic Castrate-resistant Prostate Cancer. Clin Oncol (R Coll Radiol). 2018;30(9):548-55. 46. Wong WW, Anderson EM, Mohammadi H, Daniels TB, Schild SE, Keole SR, et al. Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration resistant Prostate Cancer. Clin Genitourin Cancer. 2017;15(6):e969-e75. 47. Frantellizzi V, Farcomeni A, Follacchio GA, Pacilio M, Pellegrini R, Pani R, et al. A 3-variable prognostic score (3-PS) for overall survival prediction in metastatic castration-resistant prostate cancer treated with (223)Radium-dichloride. Ann Nucl Med. 2018;32(2):142-8. 48. Al-Ezzi EM, Alqaisi HA, Iafolla MAJ, Wang L, Sridhar SS, Sacher AG, et al. Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration resistant prostate cancer treated with Radium-223. Cancer Med. 2021;10(17):5775-82. 49. Alva A, Nordquist L, Daignault S, George S, Ramos J, Albany C, et al. Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer. Prostate. 2017;77(5):479-88.

8

221